Rezolute (RZLT) PT Raised to $9 at JMP Securities

JMP Securities analyst Jason Butler raised the price target on Rezolute (NASDAQ: RZLT) to $9.00 (from $8.00) while maintaining a Market Outperform rating.

The analyst commented, “Rezolute provided F2Q25 financial results and business updates, as it continues to advance two Phase 3 programs for ersodetug. The Phase 3 sunRIZE trial for ersodetug in CHI continues to enroll, and progress remains on track to begin enrolling U.S. patients in 2Q25."

Also, "We look to the outcome of the planned interim analysis for this trial in early 2Q25. Rezolute ended the quarter with ~$105MM in cash and remains well funded to execute on ersodetug's development.”

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Phillips 66, Marathon Merger Talks Collapsed - Semafor